SCHEMBL2819002

SCHEMBL2819002

COc1ccc(Nc2cncc(-c3cccc(NC(=O)c4cccs4)c3)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.62
MEN1 O00255 5/20 0.62
RAB9A P51151 6/20 0.61
NPC1 O15118 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
TP53 P04637 2/20 0.61
TDP1 Q9NUW8 2/20 0.53
POLB P06746 1/20 0.53
PPARG P37231 1/20 0.53
NR2E3 Q9Y5X4 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HPGD P15428 1/20 0.53
XDH P47989 1/20 0.53
SLC22A12 Q96S37 1/20 0.53
BRAF P15056 2/20 0.52
FYN P06241 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2822415 0.85 ADORA3 (0.61) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL2820197 0.83 ADORA3 (0.69) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL4198997 0.83 BRAF (0.72) XDHSLC22A12BRAFFYN
SCHEMBL2819678 0.81 MAPT (0.62) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL2818641 0.81 TSHR (0.65) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL2818890 0.80 MTNR1B (0.60) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL2822717 0.80 XDH (0.57) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL2823155 0.80 MTNR1A (0.60) KMT2AMEN1RAB9ANPC1TDP1
SCHEMBL2818742 0.80 SMO (0.58) KMT2AMEN1RAB9ATP53POLB
SCHEMBL2823124 0.80 NPC1 (0.60) KMT2AMEN1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288421-B2 neoplastic disease, autoimmune disease, transplantation related pathology and/or degenerative disease; selectively inducing apoptosis in cancer cells BASILEA PHARMACEUTICA AG (CH) 2012-10-16 US claimed
EP-1789044-B1 PHENYLAMINOPYRIDINES AND PHENYLAMINOPYRAZINES BASILEA PHARMACEUTICA AG (CH) 2010-10-27 EP claimed
US-20080221171-A1 Phenylaminopyridines BASILEA PHARMACEUTICA AG (CH) 2008-09-11 US claimed
EP-1789044-A1 PHENYLAMINOPYRIDINES Basilea Pharmaceutica AG (CH) 2007-05-30 EP claimed
WO-2006027348-A1 PHENYLAMINOPYRIDINES BASILEA PHARMACEUTICA AG (CH) 2006-03-16 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221171-A1 Phenylaminopyridines P2RY11, BCL9, TPMT KMT2A 2811/4885MEN1 2236/4885RAB9A 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.